Sexually transmitted infections caused by Chlamydia trachomatis may lead to pelvic inflammatory disease, ectopic pregnancy, infertility, and chronic pelvic pain in women. They are associated with increased risk of HIV transmission. Pregnant women may transmit infection to their newborn, causing serious medical complications.
NHANES offers an opportunity to assess the prevalence of chlamydia in the general population and to monitor trends in prevalence as prevention programs are established and expanded.
Participants aged 14-39 years were tested. Public data file includes data for persons 18-39 years of age. Please see Analytic Notes about the release of data for adolescents 14-17 years of age.
Urine specimens were processed, stored and shipped to the Division of AIDS, STD, and TB Laboratory Research, National Center for Infectious Diseases, National Centers for Disease Control and Prevention for analysis. Detailed specimen collection and processing instructions are discussed in the NHANES Laboratory/Medical Technologists Procedures Manual (LPM).
The BDProbeTec CT Chlamydia trachomatis Amplified DNA Assays are based on the simultaneous amplification and detection of target DNA, using amplification primers and a fluorescent labeled detector probe. The Strand Displacement Amplification (SDA) reagents are dried in two separate disposable microwell strips. The processed sample is added to the Priming Microwell, which contains the amplification primers, fluorescent labeled detector probe, and other reagents necessary for amplification. After incubation, the reaction mixture is transferred to the Amplification Microwell, which contains two enzymes (a DNA polymerase and a restriction endonuclease) necessary for SDA. The Amplification Microwells are sealed to prevent contamination and then incubated in a thermally controlled fluorescent reader which monitors each reaction for the generation of amplified products. There were no changes (from the previous 2 years of NHANES) to equipment, lab methods or lab site.
The data were reviewed. Incomplete data or improbable values were sent to the performing laboratory for confirmation.
The NHANES quality assurance and quality control (QA/QC) protocols meet the 1988 Clinical Laboratory Improvement Act mandates. Detailed quality control and quality assurance instructions are discussed in the NHANES Laboratory/Medical Technologists Procedures Manual (LPM).
A detailed description of the quality assurance and quality control procedures can be found on the NHANES website.
Refer to the 2011-2012 Laboratory Data Overview for general information on NHANES laboratory data.
The analysis of NHANES 2011-2012 laboratory data must be conducted using the appropriate survey design and demographic variables. The NHANES 2011-2012 Demographics File contains demographic data, health indicators, and other related information collected during household interviews as well as the sample weight variables. The demographics file may be linked to the laboratory data file using the unique survey participant identifier (i.e., SEQN).
Exam sample weights should be used for analyses. Please refer to the NHANES Analytic Guidelines and the on-line NHANES Tutorial for further details on the use of sample weights and other analytic issues.
The public release data file includes urinary chlamydia data for participants aged 18–39. Data for youth aged 14–17 years are available through the NCHS Research Data Center (RDC).
|Code or Value||Value Description||Count||Cumulative||Skip to Item|